• Florian Scotté, Eugeniu Banu, Jacques Medioni, Eric Levy, Christelle Ebenezer, Sandrine Marsan, Adela Banu, Jean Marc Tourani, Jean-Marie Andrieu, and Stéphane Oudard.
• Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France. florian,scotte@egp.aphp.fr
• Cancer. 2008 Apr 1; 112 (7): 1625-31.

BackgroundOnycholysis occurs in approximately 30% of patients treated with docetaxel. The efficacy and safety of an Elasto-Gel frozen sock (FS) was investigated for the prevention of docetaxel-induced nail and skin toxicity of the feet.MethodsPatients receiving docetaxel at a dose of 70 to 100 mg/m(2) every 3 weeks were eligible for this matched case-control study. Each patient wore an FS for 90 minutes on the right foot. The unprotected left foot acted as control. Nail and skin toxicities were assessed using National Cancer Institute Common Toxicity Criteria (version 3) and compared using a 2-sample Wilcoxon matched-pairs rank test adjusted for tied values.ResultsFifty consecutive patients were included between April 2005 and January 2007. Nail toxicity was significantly lower in the FS-protected foot compared with the control foot (grade 0: 100% versus 79%; and grade 1 and 2: 0% versus 21%, respectively) (P= .002). Skin toxicity was grade 0: 98% versus 94%; and grade 1 and 2: 2% versus 6% in the FS-protected and the control feet, respectively. The median times until toxicity occurrence were not found to differ significantly between the groups. One patient experienced discomfort because of cold intolerance.ConclusionsCold therapy using FS significantly reduced the incidence of docetaxel-induced foot nail toxicity, as previously demonstrated using frozen gloves for the hands.

31 keywords...

hide…